CI

At a glance

ClinicalIndex Comparison Record
Phase 2Completed· 62 enrolled
Drug / intervention
5Fluorouracil +5 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT04513951
NCT04513951Phase 2Completed
CompareCT.gov

Phase II Study of AVELUMAB and CETUXIMAB and Modified FOLFOXIRI as Initial Therapy for RAS Wild-type Unresectable Metastatic Colorectal Cancer Patients

Gruppo Oncologico del Nord-Ovest·interventional·Posted Aug 14, 2020·Updated Jan 9, 2025

In Brief

A Phase 2 clinical trial evaluating 5Fluorouracil, L-leucovorin, and 4 other interventions for Metastatic Colorectal Cancer. Completed, enrolled 62 participants across 1 site.

Detailed Summary

The aim of this study is to evaluate the efficacy of mFOLFOXIRI plus cetuximab and avelumab as first line treatment of patients with initially unresectable and previously untreated RAS wild-type metastatic colorectal cancer (mCRC), in terms of Progression-free Survival.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsMetastatic Colorectal Cancer
CountriesItaly
Collaborators--

Timeline

Phase 2CompletedFinished
202120222023202420252026
First PostedAug 14, 2020
Enrollment StartApr 1, 2020
Primary CompletionJun 28, 2023
Study CompletionDec 31, 2024
TodayJul 2, 2026
Enrollment to primary: 3.2 yearsPosted 5.9 years ago

Interventions

5Fluorouracildrug

phase II

L-leucovorindrug

phase II

Irinotecandrug

phase II

Oxaliplatindrug

phase II

Cetuximabdrug

phase II

Avelumabdrug

phase II